<DOC>
	<DOC>NCT00600093</DOC>
	<brief_summary>The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.</brief_summary>
	<brief_title>Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>Patient with a diagnosis of Parkinson Disease refered for surgery at our institution. Cardiac and neurosurgical procedures Inability to sign informed Consent allergy to Amantadine Congestive heart failure Arrythmia (including bradycardia below 55 bpm) renal failure (creatinin above 1.5) If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Amantadine</keyword>
</DOC>